title: Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link.
abstract: The proteasome inhibitor Bortezomib has been identified as a potent enhancer of TRAIL-induced apoptosis in several human cancers. However, the identification of the underlying molecular mechanisms of this synergistic cell death induction has been ongoing over the last years. A recent study identifies a new mechanism of action for the synergism of TRAIL and Bortezomib.
authors.affiliation: Institute for Experimental Cancer Research in Pediatrics, Goethe-University Frankfurt, Komturstr. 3a, 60528 Frankfurt, Germany. Simone Fulda. simone.fulda@kgu.de
authors.forename: Simone
authors.initials: S
authors.lastname: Fulda
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D051023:BH3 Interacting Domain Death Agonist Protein / Q000378:metabolism*; D001897:Boronic Acids / Q000494:pharmacology* / Q000627:therapeutic use; D000069286:Bortezomib; D045744:Cell Line, Tumor; D004357:Drug Synergism; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D061988:Proteasome Inhibitors; D017510:Protein Folding / Q000187:drug effects; D011719:Pyrazines / Q000494:pharmacology* / Q000627:therapeutic use; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000494:pharmacology*; D019139:Tumor Escape / Q000187:drug effects
chemical_list: D051023:BH3 Interacting Domain Death Agonist Protein; D001897:Boronic Acids; D061988:Proteasome Inhibitors; D011719:Pyrazines; D053221:TNF-Related Apoptosis-Inducing Ligand; D000069286:Bortezomib